angle

  •  

    Jeff Williams

    Chairman and CEO, NeuMoDx Molecular

    Jeff is the founding CEO of NeuMoDx Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.

    Jeff received a BS in Biology from Alma College and a MBA from the University of Michigan.

     

     

    Sundu Brahmasandra

    President, NeuMoDx Molecular

    Sundu serves as the President of NeuMoDx Molecular. Most recently, he served as the President of Life Magnetics, Inc. a spin-out from the University of Michigan developing a novel, non-microscope based platform for real-time monitoring of cell growth, death and other binding events. Prior to Life Magnetics, Sundu served as a VP of R&D/Assay Development in the Infectious Disease division at BD Diagnostics. Prior to BD, Sundu was Co-Founder and V.P. Product Development of HandyLab, Inc., where he led the development & validation of the Jaguar molecular diagnostic platform as well as proprietary nucleic acid preparation technologies and a multitude of real-time PCR assays spanning molecular diagnostics, food-borne pathogen detection, GMO testing and other applications. HandyLab was acquired by BD in Nov 2009 for more than $275 million.

    Sundu received his BS from the Indian Institute of Technology, Chennai and a PhD in Chemical Engineering from the University of Michigan in 2001.

     

  •  

    Jeff Williams

    Chairman and CEO, NeuMoDx Molecular

    Jeff is the founding CEO of NeuMoDx Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.

    Jeff received a BS in Biology from Alma College and a MBA from the University of Michigan.

     

     

    Edward Michael

    Managing Partner, LionBird, and retired EVP, Diagnostic Products, Abbott

    Ed is Managing Partner at LionBird, a venture capital firm he co-founded in 2012, which focuses on investments in early stage software companies in the healthcare, commerce and business enterprise fields. Prior to founding LionBird, Ed was at Abbott Laboratories for almost 27 years, where he was Executive Vice President, Diagnostic Products and held various other executive roles in the Legal, Medical Products, and Diagnostics divisions. During his career at Abbott, he acquired and divested businesses, founded and built a new molecular diagnostics business, and developed and executed a plan to turn around the underperforming Diagnostics division. Ed served on the Board of Directors of the Cook County Health and Hospitals System from 2012-2013, and continues to work extensively with Cook County government and health care leaders on providing health care for the poor and uninsured. He is also a member of the Boards of Directors of Telesofia, VG Bio, and Ovuline.

     

     

    Jan Garfinkle

    Founder & Managing Director, Arboretum Ventures

    Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering, extensive operating experience, and industry connections to select and nurture outstanding companies. Jan led Arboretum’s investment in HandyLab and served on the Board of Directors for five years until the company was acquired by Becton Dickinson. She presently serves as a director of NXThera, Sonitus Medical, Cerêve and NeuMoDx, and as a board observer on Uptake Medical. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions and was Founder and President of Strategic Marketing Consultants. Earlier in her career, Jan was part of the senior management team for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired and became part of Guidant Corporation.

    Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

     

     

    Nicole Walker

    Director, Baird Capital

    Nicole serves as a Director on Baird Capital’s Venture Capital team and focuses on healthcare investments. Prior to joining Baird Capital, Nicole was with Abbott Ventures, where she managed the strategic planning, market development, and product portfolio initiatives for multiple brands in discrete and continuous blood glucose monitoring. Before Abbott, she was with ONSET Ventures, where she specialized in seed and early-stage healthcare technology investments, and also worked for Guidant Corporation where she held a variety of roles within operations, product design & development, engineering management, and marketing. Nicole received a BS in Mechanical Engineering from Stanford University, her MBA from the Kellogg School of Management and her MEM (Masters of Engineering Management) from the McCormick School of Engineering at Northwestern University.

     

     

    Bill Burkoth

    Executive Director, Pfizer Ventures

    Bill is currently an Executive Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently serves on the board of directors of Biodesy, NeuMoDx Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and BBI Financial Gestão de Recursos (Rio, Brazil). Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

     

angle2